FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search
Vol 5, No 3 (2012)


3-7 493

in this paper it’s represented the information search methods review, that is used in pharmacoeconomic studies. Review of methods of critical evaluation of research is also provided.

Russian Studies

8-12 528

Abstract: lung cancer takes the second place in the general structure of incidence of malignant neoplasms in Russia. The diagnosis of a local or metastatic non small cells lung cancer (NSCLC) serves the indication to carrying out the 1st line chemotherapy. In case of progressing against or after the 1st line chemotherapy the 2nd line of treatment of NSCLC is carried out. As the 2nd line of monotherapy of NSCLC there are used docetaxel or pemetrexed and representatives of a class of target oral medicines – gefitinib and erlotinib. This article presents results of comparative pharmacoeconomical estimation of this medicines in real modern health care system of Russian Federation. According to the obtained results application of erlotinib as the 2nd line therapy of patients with local or metastatic NSCLC is more preferable than docetaxel, pemetrexed or gefitinib
from the economic point of view.

13-19 612

a total of 62 patients with a diagnosis of low back pain. Low back pain patients were randomized of two group. Patients of the first (main) group received a course of intraosseous blockades, while patients of the second (control group) received a course of conservatively treatment (analgetics, NSAIDs, myorelaxants, physical therapy). Measured direct costs at 1-year follow-up. Quality of life was measured with the Oswestry low back pain disability questionnaire, converted into utilities and transformed into quality-adjusted life years - QALY. The analysis will be performed for the health systems. Mean QALY in the first group was 0,358 and 0,134 in the second group.
The cost-utility ratio for first group was 39 090,5 RUB for 1 QALY, and for standard therapy it was 179 552,2 RUB for 1 QALY. Treatment by intraosseous blockades is dominant alternative.

20-26 793

Currently, chronic obstructive pulmonary disease (COPD) is a 5-largest cause of death worldwide, and the reduced activities of daily living, productivity and disability explain a significant economic and social damage. World Health Organization (WHO) predicts, that COPD will be a 3-largest cause of death worldwide. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of patients. We performed budget impact analysis on the basis of two bronchodilators in Russian Federation – tiotropium bromide (Spiriva) and ipratropium bromide (Atrovent) in COPD treatment. Changing treatment option from Atrovent to Spiriva provides economic benefit and permit to treat additionally
COPD patients for the same period.

27-32 1109

Abstract: pharmacoeconomic study of treatment primary open-angle glaucoma with fix combination of carbonic anhydrise inhibitors and betablockers by mean of cost-utility, willingness-to-pay, cost minimization and budget impact analysis was conducted. Results have shown, that Azarga has benefits compare with Kosopt and combination of Azopt and timolol from cost-minimization and budget impact analysis perspective and can be claimed dominant. Futhermore Azarga in comparison with Dorzopt plus is cost-effective drug, because of Azarga incremental cost-utility ratio is lower than willingness-to-pay threshold value for Russia.

33-40 712

Abstract: the pharmacoeconomic study compared the standard drug therapy (vitamin D and phosphorbinders) of secondary hyperparathyroidism (SHPT) to the using a combination of Mimpara (Cinalcet), vitamin D and phosphorbinders in patients with end-stage renal disease on dialysis. Comparison was carried out by mean of «cost-efficacy» analysis, as the main performance indicator has been selected % of patients reaching the target values of K / DOQI of the main biochemical parameters - parathyroid hormone level and CaxP. The use of Mimpara demonstrated advantages over standard treatment of secondary hyperparathyroidism to reduce the complications of the cardiovascular system and musculoskeletal system, reduce the dose of vitamin D and advantages in terms of «cost-efficacy» analysis. The cost of achieving the goals of treatment (values of K / DOQI of the main biochemical parameters) in one patient for the time horizon of 26 weeks of the first year of treatment for a combination of Mimpara, vitamin E and drugs phosphorbinders was 20,709 rubles. (Taking into account the costs of dialysis treatments), and for standard therapy - 110,092 rubles (Taking into account the costs of dialysis treatments). Thus, treatment of SHPT combination of vitamin D, drugs and phosphorbinders and Mimpara can be considered as an alternative to the dominant position of pharmacoeconomic analysis in comparison to therapy with vitamin D and phosphorbinders only.

41-46 545

to conduct analysis of basal-bolus insulin detemir/aspart in comparison with the NPH/human insulin for the treatment of patients with diabetes mellitus type 1 in Russia. We evaluate results of PREDICTIVE study using pharmacoeconomic analyses: «cost – effectiveness,» «cost – utility» and « budget impact». Analysis included the most widely known insulins: Protaphane®, Actrapid®, NovoRapid® and Levemir® . The period of analysis was 1 year. Additional costs for insulin transition (Protaphane® /Actrapid® to Levemir® /NovoRapid®) were 21774 rubles per patient/year, while the cost of an averted severe hypoglycemia was 24728 rubles. The reduced frequency of severe hypoglycemia (Levemir® /NovoRapid®) con

Drug Utilization

47-50 382

in the present research is shown that using information and computer technologies can automate the pharmacoeconomic evaluation of the rationality of the appointment and a forecast of efficiency of basic therapy of multiple sclerosis. Criteria of efficiency of immunomodulatory therapy of the multiple sclerosis, taking into account the individual characteristics of each patient, are selected.

Economic Review

51-54 356

in this paper the possibility of using the traditional methods of evaluating investment projects. Describes the various indicators of investment projects. Describes the relationship of the housing sector of the economy and social and health care.

ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)